[Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns].

Abstract

OBJECTIVE:

For the therapy of preeclamptic patients is Urapidil besides Dihydralazine another possible option for iv-therapy with good results in first clinical studies. Effects of both drugs on the newborns were observed.

METHODS:

The maternal and fetal Urapidil plasma-concentrations and cardiovascular parameters of the newborns were observed in a randomised comparative therapy-study.

RESULTS:

We found low fetal Urapidil plasma-concentrations as well as a less influence on cardiovascular parameters compared to dihydralazine.

DISCUSSION:

With Urapaidil we have another therapeutic option in preeclampsia where we could not show any negative side-effects on the newborns.

• Authors: M Schulz, J Wacker, G Bastert
• Journal: Zentralblatt fur Gynakologie (Zentralbl Gynakol) Vol. 123 Issue 9 Pg. 529-33 (Sep 2001) ISSN: 0044-4197 [Print] Germany
• Vernacular Title: Auswirkungen von Urapidil in der antihypertensiven Therapie bei Präeklampsie auf die Neugeborenen.
• PMID: 11709746 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Antihypertensive Agents
• Piperazines
• urapidil
• Dihydralazine

Topics

• Adult
• Antihypertensive Agents (blood, therapeutic use)
• Cardiovascular Physiological Phenomena (drug effects)
• Dihydralazine (blood, therapeutic use)
• Dose-Response Relationship, Drug
• Female
• Humans
• Infant, Newborn (blood)
• Maternal-Fetal Exchange
• Piperazines (blood, therapeutic use)
• Pre-Eclampsia (blood, drug therapy)
• Pregnancy
• Treatment Outcome